SVP, Global Head of Corporate Development
CStone Pharmaceuticals
Dr. Bing Yuan is currently SVP and Global Head of Corporate Development at CStone Pharmaceuticals. He is a seasoned business executive with extensive experience in business development and marketing strategy, made significant contributions to 7 oncology brands. Before joining CStone, he was Executive Director and Global Lead of Oncology BD at Merck (MSD). He focused on expanding Merck's leadership position in cancer immunotherapy, and successfully achieved 34 M&A, licensing and Keytruda collaboration deals. Before Merck, he was Marketing Executive Director at Novartis Oncology, responsible for Glivec and Afinitor brand life cycle strategy. He participated in global launch of Zykadia in lung cancer and was a core deal team member that in-licensed Jakavi from Incyte. He was three-time Novartis Oncology President Award recipient. He also served as Global Oncology Marketing Lead at Eisai in the past, managing entire oncology portfolio. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University and a MBA from Cornell University.